Page 11234..1020..»

Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro – ZAWYA

By daniellenierenberg

Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro  ZAWYA

See the original post:
Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro - ZAWYA

To Read More: Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro – ZAWYA
categoriaIPS Cell Therapy commentoComments Off on Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro – ZAWYA | dataJanuary 14th, 2024
Read All

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple…

By daniellenierenberg

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications  Marketscreener.com

See original here:
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple...

To Read More: Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple…
categoriaIPS Cell Therapy commentoComments Off on Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple… | dataMarch 1st, 2023
Read All

What is an Intrusion Prevention System? Definition … – Fortinet

By daniellenierenberg

While intrusion detection systems (IDS) monitor the network and send alerts to network administrators about potential threats, intrusion prevention systems take more substantial actions to control access to the network, monitor intrusion data, and prevent attacks from developing.

IPS evolved from IDS. IDS technology uses the same concept of identifying traffic and some of the similar techniques with the major difference being that IPS are deployed in-line and IDS are deployed off-line or on tap where they still inspect a copy of the entire traffic or flow but cannot take any preventive action. IDS are deployed to only monitor and provide analytics and visibility into the threats on the network.

Historically, IPS only reacted to cyber breaches, but this reactive stance is no longer satisfactory. IPS is now part of full network security suites, including threat monitoring, firewalls, intrusion detection, anti-virus, anti-malware, ransomware prevention, spam detection, and security analytics.

Recent trends in IPS include using AI to automate the detection process. The future of IPS technology extends network perimeter security with a multi-layered defense. Cloud IPS services perform this security function using extended detection, response, and endpoint protection.

More:
What is an Intrusion Prevention System? Definition ... - Fortinet

To Read More: What is an Intrusion Prevention System? Definition … – Fortinet
categoriaIPS Cell Therapy commentoComments Off on What is an Intrusion Prevention System? Definition … – Fortinet | dataJanuary 27th, 2023
Read All

What is an IPS Monitor? Monitor Panel Types Explained …

By daniellenierenberg

Advantages of IPS display panels:

If youve ever begun searching for a new computer screen, chances are youve probably come across the term IPS. Its at this point that you may be asking yourself,what is an IPS monitor?Andhow do I know if an IPS monitor is right for me?

To answer these questions we must first understand two things:

So, why is this important? A monitors panel technology is important because it affectswhat the monitor can doandfor which uses it is best suited.Each of the monitor panel types listed above offer their own distinctive benefits and drawbacks.

Choosing which type of monitor panel type to buy will depend largely on your intended usage and personal preference.After all, gamers, graphic designers, and office workers all have different requirements. Specific types of displays are best suited for different usage scenarios.

The specific type of LCD panel affects many different aspects of screen performance including:

Different panel technologies offer unique profiles with opinions on thebesttype of LCD being subjective and based on personal preference.

The reason for this is because none of the different monitor panel types as they are today can be classified as outstanding forallof the attributes mentioned above.

Below well take a look at how IPS, TN, and VA monitors affect screen performance and do some handy summaries of strengths, weaknesses, and best-case uses for each type of panel technology.

IPS monitors or In-Plane Switching monitors, leverage liquid crystals aligned in parallel to produce rich colors. IPS panels are defined by the shifting patterns of their liquid crystals. These monitors were designed to overcome the limitations of TN panels. The liquid crystals ability to shift horizontallycreates better viewing angles.

IPS monitors continue to be the display technology of choice for users that wantcolor accuracy and consistency. IPS monitors are really great when it comes tocolor performanceandsuper-wide viewing angles. The expansive viewing angles provided by IPS monitors help to deliver outstanding color when being viewed from different angles. One major differentiator between IPS monitors and TN monitors is that colors on an IPS monitor wont shift when being viewed at an angle as drastically as they do on a TN monitor.

IPS monitor variations include S-IPS, H-IPS, e-IPS and P-IPS, and PLS (Plane-to-Line Switching), the latter being the latest iteration. Since these variations are all quite similar, they are all collectively referred to as IPS-type panels. They all claim to deliver the major benefits associated with IPS monitors great color and ultra-wide viewing angles.

When it comes to color accuracy, IPS monitors surpass the performance of TN and VA monitors with ease. While latest-gen VA technologies offer comparative performance specs, pro users still claim thatIPS monitors reign supremein this regard.

Another important characteristic of IPS monitors is that they are able to support professional color space technologies, such asAdobe RGB. This is due to the fact that IPS monitors are able to offer more displayable colors, which help improve color accuracy.

In the past, response time and contrast were the initial weakness of IPS technology. Nowadays, however, IPS monitor response times have advanced to the point where they are even capable of satisfying gamers, thus resulting in a rising popularity inIPS monitors for gaming.

With regard to gaming, some criticisms IPS monitors include more visible motion blur coming as a result of slower response times, however the impact of motion blur will vary from user to user. In fact, mixed opinions about the drawbacks of IPS monitor for gaming can be found all across the web. Take this excerpt from one gaming technology writer for example: As for pixel response, opinions vary. I personally think IPS panels are quick enough for almost all gaming. If your gaming life is absolutely and exclusively about hair-trigger shooters, OK, youll want the fastest response, lowest latency LCD monitor. And that means TN. For the rest of us, and certainly for those who place even a modicum of importance on the visual spectacle of games, I reckon IPS is clearly the best panel technology. Read the full articlehere.

IPS monitors deliver ultra-wide 178-degree vertical and horizontal viewing angles. Graphic designers, CAD engineers, pro photographers, and video editors will benefit from using an IPS monitor. Many value the color benefits of IPS monitors and tech advances have improved IPS panel speed, contrast, and resolution. IPS monitors are more attractive than ever for general desktop work as well as many types of gaming. Theyre even versatile enough to be used in different monitor styles, so if youve ever compared an ultrawide vs. dual monitorsetup or considered the benefits ofcurved vs. flat monitors, chances are youve already come into contact with an IPS panel.

IPS Monitor Advantages:

IPS Monitor Drawbacks:

IPS Monitor Best Uses:

TN monitors, or Twisted Nematic monitors, are the oldest LCD panel types around. TN panels cost less than their IPS and VA counterparts and are a popular mainstream display technology for desktop and laptop displays.

Displays based on this monitor panel technology are ideal for cost-conscious consumers and entry-level multipurpose use.

Despite their lower perceived value, TN-based displays are the panel typepreferred by competitive gamers. The reason for this is because TN panels can achieve arapid response timeand thefastest refresh rates on the market(like this240Hz eSports monitor). To this effect, TN monitors are able toreduce blurring and screen tearingin fast-paced games when compared to an IPS or VA panel.

On the flip side,however, TN panel technology tends to be ill-suited for applications that benefit from wider viewing angles, higher contrast ratios, and better color accuracy. That being said, LED technology has helped shift the perspective and todays LED-backlit TN models offer higher brightness along with better blacks and higher contrast ratios.

The greatest constraint of TN panel technology, however, is a narrower viewing angle as TN monitors experience more color shifting than other types of panels when being viewed at an angle.

Todays maximum possible viewing angles are 178 degrees both horizontally and vertically (178/178), yet TN panels are limited to viewing angles of approximately 170 degrees horizontal and 160 degrees vertical (170 /160).

In fact, TN monitor can sometimes be easily identified by the color distortion and contrast shifting thats visible at the edges of the screen. As screen sizes increase, this issue becomes even more apparent as reduced color performance can even begin to be seen when viewing the screen from a dead-center position.

For general-purpose use, these shifts in color and contrast are often irrelevant and fade from conscious perception. However, this color variability makes TN monitors a poor choice for color-critical work like graphic design and photo editing. Graphic designers and other color-conscious users should also avoid TN displays due to their more limited range of color display compared to the other technologies.

TN monitors are the least expensive panel technology, making them ideal for cost-conscious businesses and consumers. In addition, TN monitors enjoy unmatched popularity with competitive gamers and other users who seek rapid graphics display.

TN Monitor Advantages:

TN Monitor Drawbacks:

TN Monitor Best Uses:

Vertical alignment (VA) panel technology was developed to improve upon the drawbacks of TN. Current VA-based monitors offer much higher contrast, better color reproduction, and wider viewing angles than TN panels. Variations you may see include P-MVA, S-MVA, and AMVA (Advanced MVA).

These high-end VA-type monitors rival IPS monitors as the best panel technology for professional-level color-critical applications. One of the standout features of VA technology is that it is particularly good at blocking light from the backlight when its not needed. This enables VA panels to display deeper blacks and static contrast ratios of up to several times higher than the other LCD technologies. The benefit of this is that VA monitors with high contrast ratios can deliver intense blacks and richer colors.

Contrast ratio is themeasured difference between the darkest blacks and the brightest whites a monitor can produce. This measurement provides information about the amount of grayscale detail a monitor will deliver. The higher the contrast ratio, the more visible detail.

These monitors also provide more visible details in shadows and highlights, making them ideal for enjoying videos and movies. Theyre also a good fit for games focused on rich imagery (RPG games for example) rather than rapid speed (such as FPS games).

MVA and other recent VA technologies offer the highest static contrast ratios of any panel technology. This allows for an outstanding visual experience for movie enthusiasts and other users seeking depth of detail. Higher-end, feature-rich MVA displays offer the consistent, authentic color representation needed by graphic designers and other pro users.

VA Monitor Advantages:

VA Monitor Drawbacks:

VA Monitor Best uses:

How does OLED compare to LCD?

There is another type of panel technology that differs from the monitor types discussed above and that is OLED or Organic Light Emitting Diode technology. OLEDs differ from LCDs because they use positively/negatively charged ions to light up every pixel individually, while LCDs use a backlight, which can create an unwanted glow. OLEDs avoid screen glow (and create darker blacks) by not using a backlight. One of the drawbacks of OLED technology is that it is usually pricier than any of the other types of technology explained.

Choosing the Right LCD Panel Technology

When it comes to choosing the right LCD panel technology, there is no single right answer. Each of the three primary technologies offers distinct strengths and weaknesses. Looking at different features and specs helps you identify which monitor best fits your needs.

With the lowest cost and fastest response times, TN monitors are great for general use and gaming. VA monitor offers a step up for general use. Maxed-out viewing angles and high contrast ratios make VA monitors great for watching movies and image-intensive gaming.

IPS monitors offer the greatest range of color-related features and remain the gold standard for photo editing and color-critical pro uses. Greater availability and lower prices make IPS monitors a great fit for anyone who values outstanding image quality.

LCD or Liquid Crystal Display is a type of monitor panel that embraces thin layers of liquid crystals sandwiched between two layers of filters and electrodes.

While CRT monitors used to fire electrons against glass surfaces, LCD monitors operate using backlights and liquid crystals. The LCD panel is a flat sheet of material that contains layers of filters, glass, electrodes, liquid crystals, and a backlight. Polarized light (meaning only half of it shines through) is directed towards a rectangular grid of liquid crystals and beamed through.

Liquid Crystals (LCs) are used because of their unique ability to maintain a parallel shape. Acting as both a solid and liquid, LCs are able to react quickly to changes in light patterns. The optical properties of LCs are activated by electric current, which is used to switch liquid crystals between phases. In turn, each pixel generates an RGB (red, green, blue) color based on the phase its in.

Note: When searching for monitors you can be sure to come across the term LED Panel at some point or another. An LED panel is an LCD screen with an LED (Light Emitting Diode) backlight. LEDs provide a brighter light source while using much less energy. They also have the ability to produce white color, in addition to traditional RGB color, and are the panel type used in HDR monitors.

Early LCD panels usedpassive-matrix technologyand were criticized for blurry imagery. The reason for this is because quick image changes require liquid crystals to change phase quickly and passive matrix technology was limited in terms of how quickly liquid crystals could change phase.

As a result,active-matrix technologywas invented andtransistors(TFTs) began being used to help liquid crystals retain their charge and change phase more quickly.

Thanks to active-matrix technology,LCD monitor panels were able to change images very quickly and the technology began being used by newer LCD panels.

Ultimately, budget and feature preferences will determine the best fit for each user. Among the available monitors of each panel type there will also be a range of price points and feature sets. Additionally, overall quality may vary among manufacturers due to factors related to a displays components, manufacturing, and design.

If youre interested in learning more about IPS monitors, you can take a look at some of theseprofessional monitorsto see if they would be the right fit for you.

Alternatively, if youre into gaming and are in the market for TN panel thesegaming monitoroptions may be along the lines of what youre looking for.

More:
What is an IPS Monitor? Monitor Panel Types Explained ...

To Read More: What is an IPS Monitor? Monitor Panel Types Explained …
categoriaIPS Cell Therapy commentoComments Off on What is an IPS Monitor? Monitor Panel Types Explained … | dataJanuary 27th, 2023
Read All

IPS panel – Wikipedia

By daniellenierenberg

IPS (in-plane switching) is a screen technology for liquid-crystal displays (LCDs). In IPS, a layer of liquid crystals is sandwiched between two glass surfaces. The liquid crystal molecules are aligned parallel to those surfaces in predetermined directions (in-plane). The molecules are reoriented by an applied electric field, whilst remaining essentially parallel to the surfaces to produce an image. It was designed to solve the strong viewing angle dependence and low-quality color reproduction of the twisted nematic field effect (TN) matrix LCDs prevalent in the late 1980s.[1]

The TN method was the only viable technology for active matrix TFT LCDs in the late 1980s and early 1990s. Early panels showed grayscale inversion from up to down,[2] and had a high response time (for this kind of transition, 1ms is visually better than 5ms). In the mid-1990s new technologies were developedtypically IPS and Vertical Alignment (VA)that could resolve these weaknesses and were applied to large computer monitor panels.

One approach patented in 1974 was to use inter-digitated electrodes on one glass substrate only to produce an electric field essentially parallel to the glass substrates.[3][4] However, the inventor was not yet able to implement such IPS-LCDs superior to TN displays.

After thorough analysis, details of advantageous molecular arrangements were filed in Germany by Guenter Baur et al. and patented in various countries including the US on 9 January 1990.[5][6] The Fraunhofer Society in Freiburg, where the inventors worked, assigned these patents to Merck KGaA, Darmstadt, Germany.

Shortly thereafter, Hitachi of Japan filed patents to improve this technology. A leader in this field was Katsumi Kondo, who worked at the Hitachi Research Center.[7] In 1992, engineers at Hitachi worked out various practical details of the IPS technology to interconnect the thin-film transistor array as a matrix and to avoid undesirable stray fields in between pixels.[8][9] Hitachi also improved the viewing angle dependence further by optimizing the shape of the electrodes (Super IPS). NEC and Hitachi became early manufacturers of active-matrix addressed LCDs based on the IPS technology. This is a milestone for implementing large-screen LCDs having acceptable visual performance for flat-panel computer monitors and television screens. In 1996, Samsung developed the optical patterning technique that enables multi-domain LCD. Multi-domain and in-plane switching subsequently remain the dominant LCD designs through 2006.[10]

Later, LG Display and other South Korean, Japanese, and Taiwanese LCD manufacturers adapted IPS technology.

IPS technology is widely used in panels for TVs, tablet computers, and smartphones. In particular, most IBM products was marketed as Flexview from 2004 to 2008 has an IPS LCDs with CCFL backlighting, and all Apple Inc. products marketed with the label Retina Display[11][12] feature IPS LCDs with LED backlighting since 2010.

In this case, both linear polarizing filters P and A have their axes of transmission in the same direction. To obtain the 90 degree twisted nematic structure of the LC layer between the two glass plates without an applied electric field (OFF state), the inner surfaces of the glass plates are treated to align the bordering LC molecules at a right angle. This molecular structure is practically the same as in TN LCDs. However, the arrangement of the electrodes e1 and e2 is different. Because they are in the same plane and on a single glass plate, they generate an electric field essentially parallel to this plate. The diagram is not to scale: the LC layer is only a few micrometers thick and so is very small compared with the distance between the electrodes.

The LC molecules have a positive dielectric anisotropy and align themselves with their long axis parallel to an applied electrical field. In the OFF state (shown on the left), entering light L1 becomes linearly polarized by polarizer P. The twisted nematic LC layer rotates the polarization axis of the passing light by 90 degrees, so that ideally no light passes through polarizer A. In the ON state, a sufficient voltage is applied between electrodes and a corresponding electrical field E is generated that realigns the LC molecules as shown on the right of the diagram. Here, light L2 can pass through polarizer A.

In practice, other schemes of implementation exist with a different structure of the LC molecules for example without any twist in the OFF state. As both electrodes are on the same substrate, they take more space than TN matrix electrodes. This also reduces contrast and brightness.[16]

Super-IPS was later introduced with better response times and colour reproduction.[17][unreliable source?]

Toward the end of 2010 Samsung Electronics introduced Super PLS (Plane-to-Line Switching) with the intent of providing an alternative to the popular IPS technology which is primarily manufactured by LG Display. It is an "IPS-type" panel technology, and is very similar in performance features, specs and characteristics to LG Display's offering. Samsung adopted PLS panels instead of AMOLED panels, because in the past AMOLED panels had difficulties in realizing full HD resolution on mobile devices. PLS technology was Samsung's wide-viewing angle LCD technology, similar to LG Display's IPS technology.[24]

Samsung asserted the following benefits of Super PLS (commonly referred to as just "PLS") over IPS:[25]

In 2012 AU Optronics began investment in their own IPS-type technology, dubbed AHVA. This should not be confused with their long standing AMVA technology (which is a VA-type technology). Performance and specs remained very similar to LG Display's IPS and Samsung's PLS offerings. The first 144Hz compatible IPS-type panels were produced in late 2014 (used first in early 2015) by AUO, beating Samsung and LG Display to providing high refresh rate IPS-type panels.[26][27]

Go here to see the original:
IPS panel - Wikipedia

To Read More: IPS panel – Wikipedia
categoriaIPS Cell Therapy commentoComments Off on IPS panel – Wikipedia | dataJanuary 27th, 2023
Read All

Cell and gene therapy products: what is an ATMP? – The Niche

By daniellenierenberg

If you were to see the phrase Advanced Therapy Medicinal Product (ATMP) you might guess, an advanced treatment that is a medicine? but you will not get much more from this without doing a lot more homework.

Whoever decided that cell and gene therapy products should be described as Advanced Therapies was a little short sighted as to how this phrase would age and strangely so, once the phrase was coined and used by the FDA (note that the FDA has RMAT designation) it has been picked up and used all over the world. This is a bit of a disaster from a communications perspective for a society familiar with terms including stem cells, gene therapy, cell therapy, tissue engineering, all now being lumped to some extent under the banner Advanced Therapies. But, so it is and so we go forward. Now our focus is just to understand what Advanced Therapy Medicinal Products are and what they can offer!

ATMPs are next generation pharmaceuticals based on cells, gene therapy or tissue replacement. These pharmaceuticals offer novel technologies for new options for disease treatments. Where no treatment or no cure was available for a disease ATMPs may open new doors to enable:

You can find a more technology based classification at the end of this article.

You may have heard of some ATMPs CAR T (Yescarta, Kymriah), Luxturna gene therapy for blindness, Strimvelis gene therapy against bubble boy syndrome. These cell or recombinant (cut-paste) gene-based pharmaceuticals are revolutionizing treatments around the world and it is only early days. Patients who had no treatment options or patients who had exhausted all treatment options are finding new hope in ATMPs and many lives have been saved or transformed already. This field is moving incredibly fast; all of the major pharmaceutical companies have programs in ATMP. Interestingly, the COVID19 vaccines developed by AstraZeneca/Oxford, Pfizer/BioNTech, Moderna and Janssen are based on delivery of the same recombinant (cut-paste) gene technologies as some gene therapy ATMPs but the recombinant genes delivered for ATMPs introduce disease free human gene sequences to patients instead of coronavirus spike proteins.

The coronavirus pandemic is greatly accelerating capabilities of National healthcare agencies and clinics to be able to handle ATMP type technologies and treatment of basically the entire world population with such technologies is going to create unprecedented data on their safety. The Coronavirus pandemic is no doubt accelerating the ability to treat patients with untreatable or uncurable disease by at least 10 years.

Around the world promising initiatives to address the challenges of developing these complex gene and/or cell based pharmaceuticals have been popping up and rapidly developing in the last 10 years. Some well known examples include the British Cell and Gene Therapy Catapult, the Centre for Commercialization of Regenerative Medicine (CCRM) and the ATMP Sweden National Initiative. The breadth of need is extensive and unprecedented interactions required between pharmaceutical companies, hospitals, researchers and national authorities mean that technology is arguably right now not always the greatest challenge. There are many potential therapies trying to make their way to patients but the foundations for inclusion of these therapies in our society need to be worked out. How will we pay for an ungodly expensive therapy today that cures a patient in one treatment instead of treating this patient with a relatively cheap (or expensive) pill that they need to take every day for the rest of their life? In the end the curative therapy will be cheaper for society but the models on which our healthcare is based are not built with this type of opportunity in mind. A nice summary of the non-tech challenges in ATMP development can be seen in the program of the ATMP world tour April 26-30, 2021, where world leaders are coming together to discuss their approach to solutions. ATMP ATMP world tour 2021 (atmpsweden.se).

You may also find a video by the European Medicines Agency on ATMPs to be useful (below).

For those who want to go deeper into this topic of what ATMPs are from a technology or regulatory perspective this resource may also be useful ATMP What are ATMPs? (atmpsweden.se), including the Q&A to clarify what therapies are and are not regulated as ATMPs.

It is important to understand that ATMPs are pharmaceuticals or drugs, not all cell therapies are ATMPs. For example, a blood transfusion is a cell therapy but it is not a pharmaceutical so it is not an ATMP. Why is it not a pharmaceutical? The cells used for a blood transfusion have not been modified and will do the same job they did in the donor, thus this is just a transplant and the treating doctor is responsible for ensuring the safety and efficacy of the treatment is sufficiently risk free to benefit the patient. For more complex cell therapies , where manufacture is required or where cells are transplanted to a different organ, external and independent oversight is needed to ensure that these treatments have suitably low risk and sufficient benefit to the patient. These complex treatments are regarded as pharmaceuticals (i.e. drugs) and regulated by National/Regional public health agencies (FDA/EMA) who ensure the safety, efficacy, and security of these drug products. These treatments are now obliged to comply with Good Manufacturing Practice and undergo clinical trials towards market approval. This is EXPENSIVE and thus why many cowboys are trying to get around their treatments being classified as an ATMP as they do not want to spend their profits on proving it works or is safe if they can just buy a boat instead. Even if it did work, cowboys may treat a few thousand patients in their lifetime but a product that can be industrially produced and proven to be safe and efficacious could effectively treat millions.

We are imagining a healthcare future where we can modify a patients genome, replace diseased cells or tissues and/or selectively attack and remove defective cells. This is not a game. This is the reality of patients lives. Opportunities need to be brought forward ethically and safely. Today we can give a functional immune system to a baby born without one, and bring a terminally ill cancer patient into remission, but the potential in this industry to specifically target defective cells and genes, instead of pumping the whole body with drugs or radiation, means that in the next 10-20 years we will be looking at a very different approach to healthcare. Everyone is pepped for this, the patients, the doctors, the nurses, the caretakers. There are so many opportunities for new patient treatments that industry are working together to get this moving.

This is truly an exciting space to watch!

Advanced Therapy Medicinal Products (ATMP) pharmaceuticals based on:

Related Posts

See more here:
Cell and gene therapy products: what is an ATMP? - The Niche

To Read More: Cell and gene therapy products: what is an ATMP? – The Niche
categoriaIPS Cell Therapy commentoComments Off on Cell and gene therapy products: what is an ATMP? – The Niche | dataJanuary 3rd, 2023
Read All

Cell Therapy – an overview | ScienceDirect Topics

By daniellenierenberg

Stem Cell Therapy

Cell therapy involves the direct administration of cells into the body for healing purposes. The units of therapy in this approach are single cells. For regenerative medicine, the ultimate objective of cell therapy is to establish a long-term graft with the capacity to perform organ functions. A practical example is bone marrow transplantation, in which HSC are the units of therapy, engraft in the bone marrow, and repopulate the entire blood lineage.105

Intravenous administration describes the direct injection of dissociated cells into the bloodstream using a syringe. It is the simplest delivery route for cell therapies and is used for HSC therapy in the clinic. Kidney cells, however, are different from blood cells and do not typically circulate throughout the body. The kidney is furthermore a densely-packed organ with no obvious route for stem cells to traverse from the bloodstream into the nephrons. Whether kidney stem cells have the ability to engraft and regenerate the kidney after intravenous administration therefore needs to be tested in preclinical animal models. In these experiments, the kidneys are typically subjected to acute injury. This damages the glomerular filtration barrier, which can enhance penetration of cells into the kidney and subsequent engraftment.

In one example, human iPS cell-derived cells expressing a variety of NPC and adult kidney cell markers were injected into the mouse tail vein 24 hours after administration of the nephrotoxic drug cisplatin.106 Extensive engraftment was reported in proximal tubules, which coincided with a 55% reduction in urea levels in treated mice, compared with control animals administered with saline or undifferentiated iPS cells.106 These experiments suggest a possible benefit of iPS-derived kidney cells on kidney injury. However, the isolated cells were not shown to demonstrate the ability to form kidney organoids with segmented nephrons. It is therefore unclear whether the implanted cells contained bona fide NPC or whether new nephrons were actually formed.

Intravenous administration has also been applied to adult kidney cell populations. Human glomerular epithelial transitional cells (see earlier), administered intravenously into a mouse model of chemically-induced podocytopathy, were found in glomeruli, and were associated with a decrease in proteinuria.107 These cells also contributed to tubules after acute injury.80 As these cells cannot form new nephrons, this approach seeks to repair and replace, rather than to completely regenerate.

MSC can be readily obtained, for instance from a patient's adipose tissue. Intravenous administration of MSC in experimental models can have a beneficial effect on ischemia-reperfusion injury.99,102,108 This benefit can be obtained even in the absence of MSC engraftment, likely via a paracrine effect. However, MSC administered to injured kidneys do not contribute tangibly to new nephron formation and can differentiate ectopically into undesirable fat cells or fibroblasts within glomeruli.108,109 Collectively, these findings suggest that intravenous administration of cell therapeutics may provide some benefit in cases where the glomerular filtration barrier has been compromised but may also have unwanted side effects.

Continued here:
Cell Therapy - an overview | ScienceDirect Topics

To Read More: Cell Therapy – an overview | ScienceDirect Topics
categoriaIPS Cell Therapy commentoComments Off on Cell Therapy – an overview | ScienceDirect Topics | dataNovember 22nd, 2022
Read All

Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

By daniellenierenberg

Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders and the satisfaction of customary closing conditions

See the article here:
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

To Read More: Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
categoriaIPS Cell Therapy commentoComments Off on Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update | dataNovember 6th, 2022
Read All

Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022

By daniellenierenberg

Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201 Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201

Original post:
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022

To Read More: Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
categoriaIPS Cell Therapy commentoComments Off on Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022 | dataNovember 6th, 2022
Read All

NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting

By daniellenierenberg

--Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of ILT3-positive cancer cells----Oral presentation from the lab of Dr. Fabiana Perna at the Indiana University School of Medicine to showcase research done in collaboration with NGM Bio demonstrating the rationale for the study of NGM936 for the treatment of patients with multiple myeloma--

See the rest here:
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting

To Read More: NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
categoriaIPS Cell Therapy commentoComments Off on NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting | dataNovember 6th, 2022
Read All

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

By daniellenierenberg

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am ET, to correct and clarify certain information contained in the quotation of the Chief Executive Officer. All other information remains unchanged.

Read the rest here:
Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

To Read More: Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update
categoriaIPS Cell Therapy commentoComments Off on Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update | dataNovember 6th, 2022
Read All

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver…

By daniellenierenberg

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced encouraging seladelpar data in patients with primary biliary cholangitis (PBC) that are being presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4th – 8th).

Read this article:
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver...

To Read More: CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver…
categoriaIPS Cell Therapy commentoComments Off on CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver… | dataNovember 6th, 2022
Read All

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core…

By daniellenierenberg

Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies

Here is the original post:
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core...

To Read More: Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core…
categoriaIPS Cell Therapy commentoComments Off on Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core… | dataNovember 6th, 2022
Read All

Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

By daniellenierenberg

Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference

The rest is here:
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

To Read More: Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
categoriaIPS Cell Therapy commentoComments Off on Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference | dataNovember 6th, 2022
Read All

Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection

By daniellenierenberg

Six-month outcomes are expected in second quarter of 2023 Six-month outcomes are expected in second quarter of 2023

See the rest here:
Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection

To Read More: Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection
categoriaIPS Cell Therapy commentoComments Off on Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection | dataNovember 6th, 2022
Read All

ORYZON to Give Updates on Corporate Progress in November

By daniellenierenberg

MADRID, Spain and BOSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in November.

More here:
ORYZON to Give Updates on Corporate Progress in November

To Read More: ORYZON to Give Updates on Corporate Progress in November
categoriaIPS Cell Therapy commentoComments Off on ORYZON to Give Updates on Corporate Progress in November | dataNovember 6th, 2022
Read All

PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

By daniellenierenberg

CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Board. The Board changes are effective immediately.

See the article here:
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

To Read More: PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
categoriaIPS Cell Therapy commentoComments Off on PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors | dataNovember 6th, 2022
Read All

Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver…

By daniellenierenberg

ALG-055009, a THR-? agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia

See the article here:
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver...

To Read More: Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver…
categoriaIPS Cell Therapy commentoComments Off on Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver… | dataNovember 6th, 2022
Read All

Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022

By daniellenierenberg

Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker linked to NASH histologic efficacy

Original post:
Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022

To Read More: Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
categoriaIPS Cell Therapy commentoComments Off on Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022 | dataNovember 6th, 2022
Read All

First U.S. patient receives autologous stem cell therapy to treat dry …

By daniellenierenberg

Media Advisory

Wednesday, August 31, 2022

At the National Institutes of Health, a surgical team successfully implanted a patch of tissue made from patient cells with the goal of treating advanced dry age-related macular degeneration (AMD), also known as geographic atrophy. Dry AMD is a leading cause of vision loss among older Americans and currently has no treatment.

The patient received the therapy as part of a clinical trial that is the first in the United States to use replacement tissues from patient-derived induced pluripotent stem (iPS) cells. The surgery was performed by Amir H. Kashani, M.D., Ph.D., associate professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins School of Medicine with assistance by Shilpa Kodati, M.D., staff clinician, NEI. The procedure was performed at the NIH Clinical Center in Bethesda, Maryland, under a phase 1/2a clinical trial to determine the therapys safety.

This iPS cell derived therapy was developed by the Ocular and Stem Cell Translational Research Section team led by Kapil Bharti, Ph.D., senior investigator at the National Eye Institute (NEI), part of NIH, in collaboration with FUJIFILM Cellular Dynamics Inc., and Opsis Therapeutics, based in Madison, Wisconsin. Safety and efficacy of this cell therapy was tested by the NEI preclinical team. Clinical-grade manufacturing of this cell therapy was performed at the Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, NIH.

This surgery is the culmination of 10 years of research and development at the NEI. In the NIH lab, the patients blood cells were converted to iPS cells, which can become almost any type of cell in the body. In this case, they were programmed to become retinal pigment epithelial (RPE) cells, the type of cell that degenerates in the advanced forms of dry AMD. RPE cells nourish and support light-sensing photoreceptors in the retina. In AMD, the loss of RPE leads to the loss of photoreceptors, which causes vision loss. This work was supported by the NIH Common Fund and NEI Intramural funding.

Kapil Bharti, Ph.D., senior investigator, Ocular and Stem Cell Translational Research Section, NEI

Brian Brooks, M.D., Ph.D., chief, Ophthalmic Genetics and Visual Function Branch, NEI

To schedule interviews with Drs. Bharti and Brooks, contact NEI at neinews@nei.nih.gov

NIH launches first U.S. clinical trial of patient-derived stem cell therapy to replace and repair dying cells in retina (News release)

NIH researchers rescue photoreceptors, prevent blindness in animal models of retinal degeneration (News release)

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated with Age-Related Macular Degeneration (Clinical trial information)

About the NEI: NEI leads the federal governments efforts to eliminate vision loss and improve quality of life through vision researchdriving innovation, fostering collaboration, expanding the vision workforce, and educating the public and key stakeholders. NEI supports basic and clinical science programs to develop sight-saving treatments and to broaden opportunities for people with vision impairment. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Go here to see the original:
First U.S. patient receives autologous stem cell therapy to treat dry ...

To Read More: First U.S. patient receives autologous stem cell therapy to treat dry …
categoriaIPS Cell Therapy commentoComments Off on First U.S. patient receives autologous stem cell therapy to treat dry … | dataOctober 29th, 2022
Read All

Page 11234..1020..»


Copyright :: 2024